{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:10:22Z","timestamp":1777266622622,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Bayer Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004182","name":"Nordic Council of Ministers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004182","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xphs.2025.104144","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:14:33Z","timestamp":1766506473000},"page":"104144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Can an absorptive sink improve the predictivity of biomimetic two-stage dissolution testing? Comparative IVIVC of various formulations of the poorly soluble drug emodepside"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4584-0121","authenticated-orcid":false,"given":"Jakob Tobias","family":"Lynnerup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Lillotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Oversohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4316-2398","authenticated-orcid":false,"given":"Maximilian","family":"Feldmueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Bauer-Brandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-5016","authenticated-orcid":false,"given":"Martin","family":"Brandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"M\u00fcnster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3946-0317","authenticated-orcid":false,"given":"Maximilian","family":"Karl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2025.104144_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejps.2013.04.002","article-title":"Biopharmaceutical classification of poorly soluble drugs with respect to \"enabling formulations\"","volume":"50","author":"Buckley","year":"2013","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2025.104144_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020592","article-title":"Commercially available cell-free permeability tests for industrial drug development: increatpdel 15sed sustainability through reduction of in vivo studies","volume":"15","author":"Jacobsen","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.xphs.2025.104144_bib0003","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/17425247.2016.1218465","article-title":"Oral bioavailability enhancement through supersaturation: an update and meta-analysis","volume":"14","author":"Fong","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.xphs.2025.104144_bib0004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol Rev"},{"issue":"8","key":"10.1016\/j.xphs.2025.104144_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103884","article-title":"Untangling \"dissolved\" drug species from various formulations of a poorly soluble drug: sampling methods, mechanistic insights, and IVIVC","volume":"114","author":"Lynnerup","year":"2025","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104144_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106166","article-title":"Microdialysis and nanofiltration allow to distinguish molecularly dissolved from colloid-associated drug concentrations during biomimetic dissolution testing of supersaturating formulations","volume":"174","author":"Holzem","year":"2022","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2025.104144_bib0007","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.xphs.2024.07.017","article-title":"Oral absorption from surfactant-based drug formulations: the impact of molecularly dissolved drug on bioavailability","volume":"113","author":"Holzem","year":"2024","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104144_bib0008","article-title":"In vitro dissolution\/permeation tools for amorphous solid dispersions bioavailability forecasting II: comparison and mechanistic insights","volume":"188","author":"Nunes","year":"2023","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2025.104144_bib0009","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.2042-7158.2011.01301.x","article-title":"In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants","volume":"63","author":"Fischer","year":"2011","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2025.104144_bib0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejpb.2011.04.010","article-title":"Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers","volume":"79","author":"Fischer","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2025.104144_bib0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejps.2012.04.015","article-title":"Impact of FaSSIF on the solubility and dissolution-\/permeation rate of a poorly water-soluble compound","volume":"47","author":"Frank","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104144_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106703","article-title":"Using molecularly dissolved drug concentrations in PBBMs improves the prediction of oral absorption from supersaturating formulations","volume":"194","author":"Holzem","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104144_bib0013","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejps.2016.09.018","article-title":"A novel microdialysis-dissolution\/permeation system for testing oral dosage forms: a proof-of-concept study","volume":"96","author":"Fong","year":"2017","journal-title":"Eur J Pharm Sci"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2025.104144_bib0014","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijpharm.2016.10.018","article-title":"In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT","volume":"515","author":"Kourentas","year":"2016","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2025.104144_bib0015","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpb.2012.07.009","article-title":"Drug precipitation-permeation interplay: supersaturation in an absorptive environment","volume":"82","author":"Bevernage","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"10.1016\/j.xphs.2025.104144_bib0016","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.xphs.2016.03.024","article-title":"Non-sink dissolution conditions for predicting product quality and In vivo performance of supersaturating drug delivery systems","volume":"105","author":"Sun","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104144_bib0017","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2016.09.001","article-title":"Dynamic dissolution-\/permeation-testing of nano- and microparticle formulations of fenofibrate","volume":"96","author":"Sironi","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104144_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106533","article-title":"Combining in vitro dissolution\/permeation with microdialysis sampling: capabilities and limitations for biopharmaceutical assessments of supersaturating drug formulations","volume":"188","author":"Holzem","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104144_bib0019","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpba.2018.04.042","article-title":"PermeaLoop, a novel in vitro tool for small-scale drug-dissolution\/permeation studies","volume":"156","author":"Sironi","year":"2018","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"10.1016\/j.xphs.2025.104144_bib0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11095-020-02807-x","article-title":"Drug permeability profiling using the novel Permeapad(R) 96-Well plate","volume":"37","author":"Jacobsen","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2025.104144_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.114706","article-title":"Understanding the transport of drugs across biomimetic barriers of various phospholipid compositions using a combined experimental and computational approach","volume":"253","author":"Kabedev","year":"2025","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"10","key":"10.1016\/j.xphs.2025.104144_bib0022","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1111\/bcp.14816","article-title":"Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects","volume":"87","author":"Gillon","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2025.104144_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010219","article-title":"Drug development for the treatment of onchocerciasis: population pharmacokinetic and adverse events modeling of emodepside","volume":"16","author":"Assmus","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.xphs.2025.104144_bib0024","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejpb.2023.04.026","article-title":"In vitro-in vivo relationship for amorphous solid dispersions using a double membrane dissolution-permeation setup","volume":"188","author":"Jorgensen","year":"2023","journal-title":"Eur J Pharm Biopharm"},{"issue":"12","key":"10.1016\/j.xphs.2025.104144_bib0025","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1021\/acs.molpharmaceut.7b00198","article-title":"Validation of dissolution testing with biorelevant media: an OrBiTo study","volume":"14","author":"Mann","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2025.104144_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106260","article-title":"Biopredictive capability assessment of two dissolution\/permeation assays, microFLUX and PermeaLoop, using supersaturating formulations of Posaconazole","volume":"176","author":"Holzem","year":"2022","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104144_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105532","article-title":"Dissolution\/permeation with PermeaLoop: experience and IVIVC exemplified by dipyridamole enabling formulations","volume":"154","author":"Eriksen","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104144_bib0028","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2015.11.012","article-title":"An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: design, implementation, and evaluation","volume":"82","author":"Kourentas","year":"2016","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2025.104144_bib0029","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1021\/acs.molpharmaceut.9b00799","article-title":"Application of the GastroDuo as an in vitro dissolution tool to simulate the gastric emptying of the postprandial stomach","volume":"16","author":"Schick","year":"2019","journal-title":"Mol Pharm"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925005982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925005982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:38:19Z","timestamp":1771393099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925005982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0022354925005982"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104144","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can an absorptive sink improve the predictivity of biomimetic two-stage dissolution testing? Comparative IVIVC of various formulations of the poorly soluble drug emodepside","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}],"article-number":"104144"}}